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ABSTRACT
Described in 1962, the opsoclonus-myoclonus-ataxia syndrome (OMAS) is 
a rare, neurologically debilitating disorder with distinct characteristics that 
may begin in childhood or adult life. Although many cases remain without 
etiological diagnosis, others are related to neoplasms and infectious diseases. 
We report a 41-year-old previously healthy male with an 8-day history of 
headache, vertigo, nausea, vomiting, and nystagmus. After a normal brain 
computed tomography and lymphocytic pleocytosis in cerebral spinal fluid 
(CSF), intravenous acyclovir therapy was initiated in the emergency room. 
On the third day of hospitalization, the diagnosis of OMAS was made based 
on the presence of chaotic and irregular eye movements, dysarthric speech, 
gait instability, generalized tremor, and myoclonic jerks. In the face of his 
neurological worsening, ampicillin followed by nonspecific immunotherapy 
(methylprednisolone and intravenous immunoglobulin) was prescribed, with 
mild clinical improvement. After a thorough laboratory workup, the definite 
diagnosis of neuroborreliosis was established and ceftriaxone (4 g/daily/3 
wks) and doxycycline (200 mg/day/2 mo) was administered. Toward the end 
of the ceftriaxone regimen, the neurologic signs substantially improved. We 
believe this to be the first case description of OMAS as clinical presentation of 
Brazilian Lyme disease-like syndrome (Baggio-Yoshinari syndrome).
Keywords: Opsoclonus-Myoclonus Syndrome; Lyme Neuroborreliosis; Borrelia burgdorferi.
CASE REPORT
A 41-year-old male Caucasian, who has 
lived in the city of Sao Paulo for the last 22 years 
came to the emergency room with an 8-day 
history of continuous, intense, bilateral occipital 
headache associated with photophobia, nausea, 
and vomiting. Three days after the initial symptoms, 
he had fever, myalgia, and vertigo. In the following 
days he developed slurred speech, marked gait 
instability, and imbalance. His past medical history 
was uneventful (he denied the occurrence of oral 
30
Autopsy and Case Reports 2014; 4(1): 29-37 Lino AMM, Spera RR, Campos FPF et al.
common cause of this syndrome in adults. Sodium 
valproate was prescribed for the relief of myoclonic 
movements. Ampicillin was empirically started in 
consideration of the diagnostic possibility of Listeria 
rhomboencephalitis and acyclovir was withdrawn. A 
new CSF test confirmed the lymphocytic pleocytosis 
with 210 cells/mm3 (99% lymphocytes, 1% 
neutrophils), protein was 84.7 mg/dL, glucose was 
51 mg/dL, lactate and chloride values were within 
normal limits, adenosine deaminase was 3.05 UI/L 
(RV: 9 UI/L). In spite of the partial decrease in CSF 
cellularity, the patient’s neurological deficits were 
unchanged. Methylprednisolone (1g/day/5 days) 
regimen was administered followed by a 5-day 
course of intravenous immunoglobulin (400 mg/kg/
day) with mild clinical improvement.
Cranial magnetic resonance imaging (MRI) 
showed a tenuous, poorly defined, oval-shaped 
hyper signal lesion in fluid-attenuated inversion-
recovery (FLAIR) and T2-weighted sequences, 
measuring 1.5 cm, with no diffusion restriction or 
enhancement after contrast infusion, in the left 
thalamus. No abnormal signs were found in the 
brainstem, cerebellum, or cranial nerves (Figure 1).
The electroencephalogram was normal. At 
the brainstem auditory evoked potential test, delay 
was registered in all wave latencies for the right ear, 
and in waves III and V for the left ear. However, 
all interpeak latencies were normal on both sides, 
indicating a distal cochlear nerve dysfunction in 
the right ear with preservation of intra-brainstem 
auditory pathways.
Contrast abdominal, thoracic, and pelvic 
CT, as well as testicular ultrasonography, failed 
to demonstrate any abnormalities suggestive of 
neoplasia. Prostate-specific antigen determination 
was within normal limits.
Renal and liver function tests, electrolytes, 
hepatic enzymes, blood cell count, lactic 
dehydrogenase (LDH), free-thyroxin, thyroid 
stimulating hormone (TSH), immunoglobulin 
dosage and protein electrophoresis were all 
non-contributory. Laboratory exams for systemic 
inflammatory activity disclosed C-reactive protein 
maximum value of 30 mg/L (RV: <5 mg/L) and 
erythrocyte sedimentation rate of 30 mm in the first 
hour (RV <15 mm in the first hour). ANA tested by 
indirect immunofluorescence with Hep-2 cells was 
unremarkable as was the test for rheumatoid factor.
or genital ulcers, arthritis, or any skin lesions 
preceding the recent symptoms). He was not on any 
medication and denied alcoholism, smoking, use of 
illicit drugs, or neurologic complaints in the past. He 
had no familial history of neurologic disease. He 
has six cats that are well maintained and regularly 
vaccinated. He denied traveling during the last 2 
years, but used to go camping between the age 
of 27 and 31 to a region where there were tick 
infestations.
At the emergency room, the remarkable 
physical findings included an ataxic gait, which 
worsened with the Tandem maneuver, dysarthric 
speech, and nystagmus to the right. Brain 
computed tomography (CT) was normal, and the 
analysis of cerebral spinal fluid (CSF) revealed 
lymphocytic pleocytosis with 528 cells/mm3 (91% of 
lymphocytes, 8% monocytes, and 1% neutrophils), 
protein was 76.3 mg/dL (reference value [RV]: <40 
mg/dL), glucose was 50 mg/dL (plasma glucose 
94 mg/dL, RV: >2/3 plasma glucose). Chloride and 
lactate values were in the reference range. Gram 
stain, China ink, cultures for acid-fast bacilli, fungus, 
and usual bacteria were all negative. Although the 
clinical course was not characteristic for herpetic 
meningoencephalitis, intravenous acyclovir was 
started.
On the third day of hospitalization, despite 
the maintenance of normal mental status, the patient 
presented involuntary, fast, arrhythmic, conjugated, 
multidirectional eye movements preventing him 
from fixing his gaze (opsoclonus) [video]. He also 
developed generalized rhythmic resting and action 
tremors associated with myoclonic jerks at postural 
fixation, and volitional limb movements, particularly 
in the right side. The cerebellar signs worsened, 
appearing as marked truncal-limb dyssynergia, 
bilateral limb dysmetria, dysdiadochokinesia, and 
cerebellar ataxia, which progressed to astasia and 
abasia. The motor and sensory examination (deep 
and superficial sensations) was unremarkable, as 
were all the deep tendon reflexes. The autonomic 
function and cranial nerves examinations were 
also unremarkable, except for hearing loss. The 
patient was unable to stand and walk, and became 
completely dependent for daily activities, such as 
eating, brushing teeth, shaving, and bathing.
Based on these neurological signs, the 
diagnosis of opsoclonus-myoclonus-ataxia 
syndrome (OMAS) was raised and a wide diagnostic 
workup was carried out to identify unusual infectious 
agents and immune dysfunction, the more 
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DISCUSSION
Opsoclonus-Myoclonus-Ataxia Syndrome 
(OMAS)
In 1962, Marcel Kinsbourne,1 an Austrian-
born pediatric neurologist, described six children 
with acute onset of a distinctive movement 
disorder, which was initially coined as myoclonic 
encephalopathy or Kinsbourne syndrome, and 
further known as “Dancing eyes syndrome,2-4 
opsoclonus-myoclonus,5 and ataxia opsoclonus-
myoclonus.6 The Children’s Cancer Group study 
finally called this entity opsoclonus-myoclonus-
ataxia syndrome.7,8
OMAS is a rare and debilitating neurologic 
disease, showing acute or subacute onset in 
childhood or adult life, occurring in 1–2 people per 
10 million per year.9-11 Opsoclonus is an important 
marker and a diagnostic clue for this syndrome. It is 
characterized by involuntary, chaotic, multidirectional, 
fast, conjugated eye movements (saccades), 
particularly pronounced when the patient tries to 
fix the gaze, but is also present at smooth pursuit 
and convergence, and could persist during sleep 
or eyelid closure.12 Although the pathophysiology is 
uncertain, the most accepted hypothesis suggests 
that disinhibition of the fastigial nucleus in the 
cerebellum due to dysfunction of Purkinje cells in 
Syphilis test results were negative in blood 
and CSF as well as cultures for fungus and bacteria. 
A polymerase chain reaction assay for Herpes virus 
1, 2, and 6, Varicella zoster virus, cytomegalovirus, 
and Mycobacterium tuberculosis in the CSF were 
all negative. Immunological tests for HIV were 
negative in blood and CSF, and the immunological 
window was ruled out by a negative viral load count. 
Serological tests for Dengue virus, Hepatitis B and 
C virus, Leptospira sp. were negative. Serology 
for Epstein Barr virus, toxoplasmosis, and rubella 
showed positivity for IgG but negativity for IgM.
In the meantime, the immunologic reaction 
(IgM) for Borrelia burgdorferi was positive in the 
CSF by enzyme-linked immunosorbent assay 
(ELISA) but negative in the serum (ELISA and 
Western Blott) performed in the Brazilian Lyme 
Disease Reference Laboratory1. With this result, the 
diagnosis of neuroborreliosis was highly considered 
and ceftriaxone (2 g/day) therapy was instituted for 
3 weeks, followed by doxycycline 100 mg twice daily 
for 2 months. After 7 days of use of ceftriaxone, the 
cerebellar signs and opsoclonus improved [video 2], 
the myoclonic jerks disappeared, and the patient 
was able to stand up and walk with assistance.
1  Medical Research Laboratory in Rheumatology – LIM 17 – Faculdade de 
Medicina da Universidade de São Paulo
Figure 1 – Cranial MRI. A – FLAIR axial imaging; B – T2 coronal imaging. Both images show a tenuous 
hyper-signal in the left thalamic region (arrows) compatible with vasogenic edema or gliosis. Note the lack of 
interruption of the hematoencephalic barrier or cytotoxic edema.
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clinical presentation and the early severe disability 
of the case reported herein were in accordance with 
published data.
In over 50% of adult patients, OMAS 
is a paraneoplastic presentation, with small-
cell lung, breast, and ovarian cancers the most 
commonly identified neoplasms.2,15 Rarer oncologic 
associations include melanoma,21-23 and other 
neoplasms of the gynecologic tract,10,24-27 as well as 
cancers of the urologic,15,28,29 hematologic,30-32 and 
gastrointestinal systems.15 Infections (mainly virus), 
idiopathic cases, and rarely toxic or metabolic 
disturbances account for the other half. In our case, 
an infectious cause was identified after an extensive 
laboratory investigation.
In both idiopathic and paraneoplastic 
cases, the imaging diagnostic workup generally 
shows normal CT and MRI.2,15 In our case, the 
MRI showed a tenuous and unspecific thalamic 
hyper-signal in T2-weighted and FLAIR sequences. 
Even though the same findings had been 
described in one idiopathic case by Bataller et al.,15 
Kobayashi et al.33 found thalamic lesions in the 
autopsy of a Borrelia burgdorferi-seropositive 
chronic encephalomyelopathy. Furthermore, blood 
and CSF tests are most useful in diagnosing 
an infection, but do not confirm or exclude a 
paraneoplastic or autoimmune etiology. Among the 
cases of immunologic etiology, CSF analysis may 
show normal results or mild increase in protein 
(47-137 mg/dl) and/or lymphocytic pleocytosis (8-
98 cells/mm3).2 Higher cell counts do not rule out 
idiopathic or paraneoplastic causes, but should raise 
the suspicion of an isolated or associated infection 
as observed in our patient. In four previously 
reported patients with Borrelia-associated OMAS, 
the cell counts ranged from 28 to 244 cells/mm3 and 
the remaining CSF characteristics were very similar 
to our case.34-37
The pathophysiology of the OMAS remains 
obscure. In idiopathic and paraneoplastic cases, 
the tissue dysfunction has been attributed to 
humoral and/or cellular immune attack affecting the 
structures belonging to fastigial nucleus-Purkinje 
cells network. In this setting, several antibodies 
against cell surface or intracellular structures of 
nervous system have been identified, such as, 
glycine receptor, Hu (ANNA-1), Ri (ANNA-2), 
glutamate receptor, neurofilament, Yo, Ma1, Ma2, 
amphiphysin, CRMP-5/anti-CV2, and Zic.2,15,20,32,38-45 
Although these antibody studies have contributed 
to understanding of immunopathogenesis, most 
the dorsal vermis or their inhibitory projections to the 
fastigial nucleus.12 Thus, affecting this network can 
cause opsoclonus independently of any etiological 
factor. Often, opsoclonus is accompanied by 
myoclonus, characterized by sudden, brief, shock-
like involuntary movements, typically postural or 
movement-induced, compromising the trunk, the 
upper and lower limbs more frequently, but also 
may occur in the face, tongue, and palate.13-15 
The myoclonic jerks can be so intense that they 
cause incoordination and falls, and can hamper 
the classical signs of cerebellar dysfunction, such 
as imbalance, dysarthria, and dysmetria. Thus, the 
ataxia (gait instability or imbalance) could result 
from myoclonus, cerebellar involvement, or both. 
To these three cardinal signs, cognitive, behavioral, 
and variable degrees of encephalopathy may also 
be associated. All these neurological signs are not 
necessarily present together at the onset of the 
syndrome.
In children, the OMAS occurs equally in 
both genders, commonly before 3 years of age. In 
about half of patients it is seen as a paraneoplastic 
syndrome most commonly associated with 
neuroblastic tumors, with neuroblastoma in more 
than half the pediatric cases.1,10,16-18 Infectious, post-
infectious, post-vaccinal, and idiopathic cases were 
also reported. The clinical presentation, detection 
of autoantibodies, response to immunosuppressive 
treatment, and the long-term outcome are similar 
concerning the idiopathic and neuroblastoma-
associated cases.18 Neuroblastoma-associated 
OMAS is frequently has a favorable prognosis.7,8 
Long-term follow-up studies have shown normal or 
near-normal motor outcome along with cognitive 
and neuropsychological deficits (language, 
attention, memory, visuomotor, and working 
memories) in almost 80% of pediatric patients.6,7,18 
The identified risk factors for worse outcome were 
younger age, severe initial presentation, delayed 
immunosuppressive treatment, and relapses with 
steroid-dose tapering.18,19
Adult-onset OMAS is much less frequent. The 
literature is limited to case reports and small series 
that showed no gender predominance and 48.5 
years (range 18-80 years) as median age of onset.2,15 
In general, the disease progresses rapidly within a 
median time of 4 weeks with severe disability in most 
patients. In about 35% of patients other coexisting 
neurological signs may be associated, including 
mild behavioral, cognitive, and/or mood changes; 
encephalopathy; cranial nerve palsies; seizure; or 
Lambert-Eaton myasthenic syndrome.2,15,20 The 
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be localized or disseminated, defined by the 
occurrence of erythema migrans, neuroborreliosis, 
carditis, or lymphocytoma.65 In the late-LD the usual 
manifestations are arthritis without neurological 
disease, acrodermatitis chronica atrophicans, or 
rarely central or peripheral neurological deficits. 
Chronic Lyme disease is poorly defined and 
most associated with persistent pain, fatigue, or 
neurocognitive complaints.65
In considering the extreme difficulty in 
demonstrating Borrelia organisms by PCR and 
cultures of CSF, and in view of dramatic clinical 
improvement with antimicrobial therapy, it was 
hypothesized that tissue-adhered spirochete, 
mainly in oligodendrocytes, is essential for disease 
manifestations, and the tissue damage is amplified 
by local immune response that encompasses 
expression of several pro-inflammatory cytokines 
and antibodies generated in some extent by 
molecular mimicry.66
Borreliosis’ laboratory workup is sometimes 
challenging since it relies on indirect detection 
methods.67 ELISA is the method for specific 
antibodies screening followed by immunoblot when 
samples are ELISA-positive, in the serum. Diagnostic 
sensitivity of ELISA for acute Borreliosis ranges 
from 70% to 90%.67 Intrathecal detection of Borrelia-
specific antibody is important for neuroborreliosis 
diagnosis. These antibodies are exclusively 
detected in the cerebrospinal fluid (CSF) in 10% 
to 70% of the patients.68,69 When these antibodies 
are detected in both, serum and CSF, the antibody-
index67,70 will diagnose the intrathecal specific-
antibody production with 80% of sensitivity. This 
index is useful for the cases with less than 6-month 
of disease. Protein chain reaction and cultures may 
be useful in early infection, but microscope-based 
assays, lymphocyte transformation test, and others 
are not currently recommended. Considering the 
European criteria67 for neuroborreliosis (Table 1), 
our patient received the diagnosis of definite 
neuroborreliosis.
In Brazil, the study of LD started in 1989 
and until now much of the knowledge on Brazilian 
borreliosis is due to the research effort of a 
multidisciplinary team headed by Dr. Natalino H. 
Yoshinari.68,71 In a preliminary study of 19 patients, 
Yoshinari and coworkers found that 31.5% had 
skin lesions, 31.5% had arthritis, and 42% had 
neurological disorders.70 Particularly analyzing 
the neurological manifestation in 30 patients with 
Brazilian borreliosis, the same group showed 
OMAS patients present negative results in blood 
and CSF, limiting their diagnostic value. In addition, 
B and T cells expansion, favorable response to 
rituximab therapy, and OMAS occurrence during 
immune reconstitution phase in HIV infection have 
raised the role for cell-mediated mechanisms.46-48
Parainfectious causes may be diverse and 
include agents such as cytomegalovirus, EBV, 
Coxsackie virus, West Nile virus, HIV, varicella-zoster 
virus, Influenza A virus, hepatitis C virus, Mycoplama 
pneumoniae, Salmonella sp., Ricketsia, group A 
streptococci, mumps, Lyme Disease (LD), and 
psittacosis.2,10,14,17,34,36,49-59 OMAS was also described 
after measles, mumps, and rubella vaccine.60 In HIV 
infection, Kanjanasut et al.57 suggest that OMAS 
occurs at the time of seroconversion or during the 
immune reconstitution inflammatory response, what 
justified the request of HIV viral load count in the 
presence of a negative serology detected in our 
patient.
Borreliosis
LD is a well-known infectious disease in the 
USA and Europe. In 1975, Steere et al.61 described 
51 patients with arthritis of unknown cause and 
hypothesized an arthropod transmission, possibly 
a tick, due to findings of skin lesions in 25% of 
the patients. This lesion was similar to erythema 
chronicum migrans reported in 1909 in Europe, 
which had been associated with tick bites and 
clinical manifestations such as neuropathic pain, 
paralysis, or meningitis. From 1975 to 1984, the 
Yale University group reported the clinical spectrum 
of LD, which included the nervous system, the heart, 
and the joints.62
The infectious agent in LD was identified 
in 1982 by Burgdorfer et al.63 and further named 
as Borrelia burgdorferi (sensu stricto). Nowadays, 
tick-borne Borrelia spp. encompass three major 
phylogenetic groups, of which the Lyme borreliosis 
group—formerly named B. burgdorferi sensu lato—
has 19 species with at least 10 being pathogenic 
to human beings.64 In North America, B. burgdorferi 
sensu stricto is the main LD pathogenic agent, while 
in Europe there are at least five pathogenic species, 
causing a wide clinical spectrum.
Clinically, LD is conceptually divided 
into early and late phases, and chronic or post-
Lyme borreliosis syndrome. The early-LD can 
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progression, and the emergency treatment was 
acyclovir. Specific treatment was only started after a 
positive result of immunologic reaction for Borrelia; 
our patient showed an important improvement after 
ceftriaxone in accordance with reported patients.
CONCLUSION
OMAS best treatment should always be, 
whenever possible, directed to the etiology. In 
idiopathic and paraneoplastic cases, the treatment 
and outcome are hard to evaluate and compare 
due to large drug variability among different series, 
as well as the number of cases in each series. 
Treatment options include high-dose corticosteroid, 
intravenous immunoglobulin, and plasmapheresis, 
isolated or combined.2 In general, parainfectious 
OMAS cases have a favorable prognosis and full 
recovery.59,74 In the literature, neuroborreliosis has 
been treated with parenteral antibiotics (ceftriaxone), 
although some European studies have suggested 
that oral doxycycline is as effective as ceftriaxone.65
To the best of our knowledge, this is the 
first case report of neuroborreliosis manifested as 
OMAS in Brazil, and probably the sixth case in the 
English language literature. Therefore, the authors 
call attention to this diagnostic possibility when 
searching the etiology of OMAS.
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